School of Pharmacy, University of Otago, PO Box 56, Dunedin, 9054, New Zealand.
Glasgow Royal Infirmary, Glasgow, Scotland, UK.
Clin Pharmacokinet. 2017 Dec;56(12):1555-1566. doi: 10.1007/s40262-017-0541-5.
Warfarin acts by inhibiting the reduction of vitamin K (VK) to its active form, thereby decreasing the production of VK-dependent coagulation proteins. The aim of this research is to develop a joint model for the VK-dependent clotting factors II, VII, IX and X, and the anticoagulation proteins, proteins C and S, during warfarin initiation.
Data from 18 patients with atrial fibrillation who had warfarin therapy initiated were available for analysis. Nine blood samples were collected from each subject at baseline, and at 1-5, 8, 15 and 29 days after warfarin initiation and assayed for factors II, VII, IX and X, and proteins C and S. Warfarin concentration-time data were not available. The coagulation proteins data were modelled in a stepwise manner using NONMEM Version 7.2. In the first stage, each of the coagulation proteins was modelled independently using a kinetic-pharmacodynamic model. In the subsequent step, the six kinetic-pharmacodynamic models were combined into a single joint model.
One patient was administered VK and was excluded from the analysis. Each kinetic-pharmacodynamic model consisted of two parts: (1) a common one-compartment pharmacokinetic model with first-order absorption and elimination for warfarin; and (2) an inhibitory E model linked to a turnover model for coagulation proteins. In the joint model, an unexpected pharmacodynamic lag was identified and the estimated degradation half-life of VK-dependent coagulation proteins were in agreement with previously published values. The model provided an adequate fit to the observed data.
The joint model represents the first work to quantify the influence of warfarin on all six VK-dependent coagulation proteins simultaneously. Future work will expand the model to predict the influence of exogenously administered VK on the time course of clotting factor concentrations after warfarin overdose and during perioperative warfarin reversal procedures.
华法林通过抑制维生素 K(VK)还原为其活性形式来发挥作用,从而减少 VK 依赖性凝血蛋白的产生。本研究旨在开发一种用于华法林起始时 VK 依赖性凝血因子 II、VII、IX 和 X 以及抗凝蛋白蛋白 C 和 S 的联合模型。
可用于分析的资料来自 18 例患有心房颤动并开始华法林治疗的患者。每个受试者在基线时采集 9 份血样,并在华法林起始后 1-5、8、15 和 29 天进行因子 II、VII、IX 和 X 以及蛋白 C 和 S 的检测。未获得华法林浓度-时间数据。使用 NONMEM 版本 7.2 以逐步方式对凝血蛋白数据进行建模。在第一阶段,使用动力学-药效学模型分别对每个凝血蛋白进行建模。在随后的步骤中,将这六个动力学-药效学模型组合成一个单一的联合模型。
一名患者接受了 VK 治疗,因此被排除在分析之外。每个动力学-药效学模型都由两部分组成:(1)一个具有一级吸收和消除的华法林的通用单室药代动力学模型;(2)与凝血蛋白周转率模型相关联的抑制 E 模型。在联合模型中,发现了一个意外的药效学滞后,估计的 VK 依赖性凝血蛋白的降解半衰期与先前发表的值一致。该模型对观察数据提供了适当的拟合。
该联合模型代表了首次同时定量华法林对所有六种 VK 依赖性凝血蛋白的影响的工作。未来的工作将扩展该模型,以预测外源性给予 VK 对华法林过量和围手术期华法林逆转过程中凝血因子浓度时间过程的影响。